Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22

Benzinga · 2d ago
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.